Abstract:T-cells genetically engineered to express a chimeric antigen receptor (CAR) have shown remarkable results in patients with B-cell malignancies, including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma, with some promising efficacy in patients with multiple myeloma. However, the efficacy of CAR T-cell therapy is still hampered by local immunosuppression and significant toxicities, notably cytokine release syndrome (CRS) and neurotoxicity. The tumor microenvironment (TME) has been identified to play a major role in preventing durable responses to immunotherapy in both solid and hematologic malignancies, with this role exaggerated in solid tumors. The TME comprises a diverse set of components, including a heterogeneous population of various cells and acellular elements that collectively contribute towards the interplay of pro-immune and immunosuppressive signaling. In particular, macrophages, myeloid-derived suppressor cells, regulatory T-cells, and cell-free factors such as cytokines are major contributors to local immunosuppression in the TME of patients treated with CAR T-cells. In order to create a more favorable niche for CAR T-cell function, armored CAR T-cells and other combinatorial approaches are being explored for potential improved outcomes compared to conventional CAR T-cell products. While these strategies may potentiate CAR T-cell function and efficacy, they may paradoxically increase the risk of adverse events due to increased pro-inflammatory signaling. Herein, we discuss the mechanisms by which the TME antagonizes CAR T-cells and how innovative immunotherapy strategies are being developed to address this roadblock. Furthermore, we offer perspective on how these novel approaches may affect the risk of adverse events, in order to identify ways to overcome these barriers and expand the clinical benefits of this treatment modality in patients with diverse cancers. Precise immunomodulation to allow for improved tumor control while simultaneously mitigating the toxicities seen with current generation CAR T-cells is integral for the future application of more effective CAR T-cells against other malignancies.

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

CAR-T Treatment for Cancer: Prospects and Challenges

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy.

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Tumor Buster - Where Will the CAR-T Cell Therapy ‘missile’ Go?

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Extant challenges and optimization strategies for CAR-T cell therapy for solid tumors

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system